iX Biopharma Past Earnings Performance
Past criteria checks 0/6
iX Biopharma has been growing earnings at an average annual rate of 2.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 29.2% per year.
Key information
2.3%
Earnings growth rate
7.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 29.2% |
| Return on equity | -248.7% |
| Net Margin | -181.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How iX Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 6 | -11 | 7 | 2 |
| 31 Mar 24 | 6 | -10 | 7 | 2 |
| 31 Dec 23 | 6 | -10 | 7 | 2 |
| 30 Sep 23 | 6 | -10 | 8 | 2 |
| 30 Jun 23 | 6 | -10 | 9 | 3 |
| 31 Mar 23 | 5 | -13 | 9 | 3 |
| 31 Dec 22 | 4 | -16 | 9 | 3 |
| 30 Sep 22 | 9 | -10 | 9 | 3 |
| 30 Jun 22 | 14 | -5 | 9 | 2 |
| 31 Mar 22 | 14 | -3 | 10 | 2 |
| 31 Dec 21 | 14 | -2 | 10 | 3 |
| 30 Sep 21 | 8 | -5 | 9 | 3 |
| 30 Jun 21 | 2 | -8 | 8 | 3 |
| 31 Mar 21 | 2 | -8 | 8 | 3 |
| 31 Dec 20 | 2 | -8 | 8 | 3 |
| 30 Sep 20 | 1 | -9 | 8 | 2 |
| 30 Jun 20 | 1 | -10 | 8 | 2 |
| 31 Mar 20 | 1 | -12 | 8 | 3 |
| 31 Dec 19 | 1 | -12 | 8 | 3 |
| 30 Sep 19 | 1 | -13 | 8 | 3 |
| 30 Jun 19 | 1 | -13 | 8 | 4 |
| 31 Mar 19 | 1 | -14 | 8 | 6 |
| 31 Dec 18 | 0 | -16 | 8 | 7 |
| 30 Sep 18 | -1 | -15 | 7 | 8 |
| 30 Jun 18 | 0 | -15 | 7 | 8 |
| 31 Mar 18 | 2 | -14 | 8 | 6 |
| 31 Dec 17 | 3 | -13 | 8 | 6 |
| 30 Sep 17 | 7 | -10 | 8 | 6 |
| 30 Jun 17 | 6 | -7 | 8 | 5 |
| 31 Mar 17 | 6 | -4 | 7 | 5 |
| 31 Dec 16 | 6 | -4 | 7 | 5 |
| 30 Sep 16 | 6 | -6 | 6 | 6 |
| 30 Jun 16 | 6 | -8 | 7 | 6 |
| 31 Mar 16 | 6 | -11 | 6 | 5 |
| 31 Dec 15 | 7 | -11 | 6 | 5 |
| 30 Sep 15 | 7 | -11 | 6 | 5 |
| 30 Jun 15 | 7 | -11 | 6 | 5 |
| 31 Mar 15 | 6 | -8 | 5 | 3 |
| 31 Dec 14 | 5 | -6 | 4 | 3 |
| 30 Sep 14 | 3 | -4 | 3 | 2 |
| 30 Jun 14 | 2 | -3 | 2 | 1 |
Quality Earnings: 42C is currently unprofitable.
Growing Profit Margin: 42C is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 42C is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare 42C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 42C is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.3%).
Return on Equity
High ROE: 42C has a negative Return on Equity (-248.71%), as it is currently unprofitable.